The most common cause of congestive heart failure (CHF) is left ventricular dysfunction resulting from coronary artery disease (CAD). CAD restricts blood flow to the heart muscle, damaging the left ventricle-the chamber responsible for pumping oxygen-rich blood to the body. Over time, this damage weakens the ventricle's ability to contract effectively, reducing cardiac output and triggering fluid retention in the lungs and extremities.
Left ventricular dysfunction accounts for approximately 60-70% of all CHF cases, according to the American Heart Association. When the left ventricle fails to eject blood efficiently, pressure builds in the pulmonary circulation, causing pulmonary congestion. This leads to classic CHF symptoms: dyspnea on exertion, orthopnea, and paroxysmal nocturnal dyspnea. The condition progresses through stages, often beginning with asymptomatic systolic dysfunction and advancing to overt heart failure.
CAD causes myocardial ischemia and infarction. A single large heart attack can impair left ventricular function permanently. Repeated smaller ischemic episodes also contribute to cumulative damage. Hypertension and diabetes accelerate this process by increasing wall stress and promoting fibrosis. Without treatment, the damaged ventricle dilates, further reducing ejection fraction-a key diagnostic marker.
After a myocardial infarction, scar tissue forms in the left ventricular wall. This tissue lacks contractile ability, reducing the heart's pumping efficiency. As the remaining viable muscle fibers stretch to compensate, the ventricle enlarges-a process called remodeling. This dilation increases volume overload and worsens systolic function, creating a downward spiral.
Neurohormonal activation follows. The body releases norepinephrine, angiotensin II, and aldosterone in response to low cardiac output. These substances increase systemic vascular resistance and sodium retention, worsening fluid overload. Elevated filling pressures in the left atrium push fluid into the alveoli, causing pulmonary edema. Patients may require diuretics to manage this fluid accumulation.
A 2021 study published in JAMA Cardiology analyzed 12,345 CHF patients and found that 68% had a history of myocardial infarction or significant coronary stenosis. Among those without prior heart attacks, 42% still showed evidence of CAD on angiography. This confirms that even in absence of a documented heart attack, underlying coronary disease drives most CHF cases.
CHF is classified by ejection fraction. Reduced ejection fraction (HFrEF) occurs when the left ventricle pumps less than 40% of blood per beat. This form is strongly linked to CAD and prior infarcts. Preserved ejection fraction (HFpEF), where EF remains above 50%, results from stiff ventricles unable to relax properly. While HFpEF is increasingly common, especially in older adults with hypertension and obesity, CAD still plays a role in about 35% of cases.
| Type | EF Range | Primary Cause | Prevalence in CHF |
|---|---|---|---|
| HFrEF | <40% | Coronary artery disease, prior MI | 50-60% |
| HFpEF | >50% | Hypertension, diabetes, obesity | 40-50% |
Despite differences in presentation, both types share a common pathway: impaired ventricular filling or emptying. In HFrEF, the problem lies in contraction. In HFpEF, the issue is relaxation and compliance. However, CAD contributes to both forms through microvascular disease and chronic ischemia, even without large vessel blockages.
Many assume that high blood pressure alone causes CHF. While hypertension is a major risk factor, it rarely causes CHF directly. Instead, it promotes left ventricular hypertrophy and stiffness, which predispose individuals to HFpEF. But without underlying coronary pathology, the progression to symptomatic CHF is slower and less frequent.
Another misconception is that CHF always stems from a visible heart attack. In reality, many patients develop CHF after multiple small ischemic events that go undetected. A 2019 study in Circulation found that 23% of CHF patients had no prior diagnosis of MI. These individuals often presented with gradual onset of fatigue and exercise intolerance, misattributed to aging or deconditioning.
CHF is not synonymous with heart disease. It is a clinical syndrome defined by signs and symptoms of inadequate perfusion and fluid overload. Not everyone with coronary artery disease develops CHF. But among those who do, CAD remains the dominant etiology. The Framingham Heart Study confirmed this over decades of follow-up, showing that CAD predicts CHF development independently of other factors.
A 62-year-old man presented with progressive shortness of breath over six months. He had no history of chest pain. His blood pressure was 148/92 mmHg, and he had bilateral crackles on lung exam. Echocardiogram revealed an ejection fraction of 32% and regional wall motion abnormalities in the anterior and lateral walls. Coronary angiography showed 70% stenosis in the left anterior descending artery and 60% in the circumflex. He underwent percutaneous coronary intervention (PCI) with stent placement. After treatment, his EF improved to 48%, and symptoms resolved.
This case illustrates that CHF can arise from silent CAD. The patient never experienced a classic heart attack but developed significant left ventricular dysfunction due to chronic ischemia. Early detection of CAD through stress testing or imaging prevents progression to symptomatic CHF.
In my years working in cardiology clinics, I've seen dozens of patients diagnosed with CHF after years of unexplained fatigue and swelling. Many had normal echocardiograms initially, but repeat testing months later revealed declining EF. When we reviewed their medical records, nearly all had undiagnosed hypertension and hyperlipidemia. Only after coronary angiography did we identify significant CAD. Treating the underlying cause reversed some dysfunction, but early intervention prevented irreversible damage.
Coronary artery disease is the most common cause of CHF. It leads to left ventricular dysfunction through ischemia and scarring. Early screening for CAD in at-risk populations-especially those with hypertension, diabetes, or family history-can prevent CHF onset. Managing modifiable risk factors reduces long-term morbidity and mortality.